Loading...
APEN logo

Apollo Endosurgery, Inc.NasdaqGM:APEN 주식 보고서

시가총액 US$579.7m
주가
n/a
내 적정 가치
해당 없음
1Y67.8%
7D0.8%
1D
포트폴리오 가치
​
보기

Apollo Endosurgery, Inc.

NasdaqGM:APEN 주식 리포트

시가총액: US$579.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Apollo Endosurgery (APEN) 주식 개요

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for gastrointestinal therapeutic endoscopy. 자세히 보기

APEN 펀더멘털 분석
스노우플레이크 점수
가치 평가0/6
미래 성장2/6
과거 실적0/6
재무 건전성5/6
배당0/6

강점

수익은 연간 32.05% 증가할 것으로 예상됩니다.

위험 분석

지난 1년 동안 주주가 희석되었습니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.


APEN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Apollo Endosurgery, Inc. 경쟁사

가격 이력 및 성과

Apollo Endosurgery 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가US$10.00
52주 최고가US$10.30
52주 최저가US$3.49
베타2.32
1개월 변동0.50%
3개월 변동1.11%
1년 변동67.79%
3년 변동360.83%
5년 변동70.94%
IPO 이후 변동-17.76%

최근 뉴스 및 업데이트

분석 기사 • Apr 03

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 • Nov 30

Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Recent updates

분석 기사 • Apr 03

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 • Nov 30

Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Aug 05

Is Apollo Endosurgery (NASDAQ:APEN) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Aug 04

Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings

Apollo Endosurgery came in with another strong quarter of top-line growth whilst growing gross margins on the same. The company saw substantial growth in each of its key segments, coupled with regulatory momentum in its Apollo ESG and REVISE series. Valuations are also supportive and we look to be getting shares on the cheap here at ~4.3x book value, as illustrated. We rate APEN a buy and value its stock at $7.97 per share. Investment Summary We continue our medtech earnings coverage with Apollo Endosurgery, Inc. (APEN), manufacturer of bariatric surgery systems. It was a strong Q2 FY22 for the company with upsides in revenue versus consensus, although it missed estimates below the bottom line. Despite this, fundamental momentum continues brewing for the company, and we note it's caught a bid in H2 FY22 alongside the broad sector. Valuations are supportive and we are paying ~4x book value for a company that grew its top 10 accounts by more than 53% YoY last quarter. With this in mind, we rate APEN buy with price target of $7.97. Exhibit 1. APEN 6-month price target Data: Refinitiv Q2 earnings illustrate current investor challenges Second-quarter earnings were mixed with upsides versus consensus in revenue but a miss in EPS. Worldwide revenue was 16% higher YoY at $19 million with ~310bps of forex tailwinds. Turnover increased due to an 18% increase in US product sales and 15% ex-US, adjusted to 23% on constant currency. The company's top 10 accounts saw a 53% YoY increase. Segmentally, Endoscopic Suturing System ("EES") sales stretched up 23% YoY to $2.4 million backed by demand for OverStitch and X-Tack. Meanwhile, its intragastric balloon ("IGB") segment grew 6% YoY. As seen in Exhibit 2, it was an above-average performance for the company, with its strongest quarterly result in years. Exhibit 2. Quarterly operating performance has been ratcheting up across FY21 to date, with share price and top-line fundamentals starting to converge Data: HB Insights; APEN SEC Filings Gross margin on these revenues lifted ~180ps YoY to 56.8% from higher product sales. As seen above, it continues to curl up alongside top-line performance. This is a bullish factor seeing the company is strengthening margins into a weakening global economic outlook. Moving down the P&L, OPEX increased to $17.6 million as the company increased its salesforce headcount in H2 FY21, plus the marketing spend with this. Operating loss on this was ~$6.5 million. It carried this down to a net loss of $10.4 million for the quarter, versus a net loss of $3 million the quarter prior. The delta was attributed to the forgiveness of the Paycheck Protection Program ("PPP") loan a year beforehand. The company left the quarter well capitalized with $140 million in "committed cash" despite a net loss on CFFO of $14.7 million, worse than the loss of $6.4 million in Q2 FY21. Ex-committed cash, it had ~$75.5 million in cash on the balance sheet. As seen in Exhibit 3, on its net cash spend of $14.7 million and ending balance of $~$75.5 million for the quarter, we estimate the company has ~1.5 years of runway left before having to re-evaluate the situation. Exhibit 3. Data: HB Insights Estimates; APEN SEC Filings With the exit momentum leaving Q2 management reiterated FY22 full-year guidance. This expects to land between $73-75 million with potential 400bps of forex headwinds. Regulatory tailwinds The company also received the nod from the FDA for De Novo marketing authorization for Apollo ESG and Apollo REVISE. Apollo ESG is an interesting segment with favourable economics tied into the mix. It is used in bariatric surgery, or treatment of patients with obesity. Both systems are the first FDA-authorized systems for "endoscopic sleeve gastroplasty". This is a minimally invasive procedure to help obesity patients in reduction of body mass. APEN indicates it for those with BMI range of 30–50kg/m2 who require bariatric surgery. Both systems and the gastroplasty procedure were also featured in the publication of the MERIT study in late July, in the LANCET journal. Per the company's investor presentation yesterday, from the study readouts: The MERIT study proves that ESG is scalable and can be offered in outpatient endoscopy practices by surgeons or gastroenterologists, with an excellent safety profile, without mortality, and with predictable conservatively managed adverse events. Intra-operative hardware used in the Apollo ESG and Apollo REVISE procedures. Image: APEN Valuation Shares are trading at around 4.2x book value and 4x sales, both below the GICS Industry median respectively. The peer group is a strong one and Apollo's lack of profitability makes it difficult to assign a concrete valuation. It printed a quarterly ROA of -8.6% and this is in line with longer term trends. Investors also realize a negative 22% ROE from the most recent quarter's results.
분석 기사 • Mar 02

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Aug 04

Is Apollo Endosurgery, Inc. (NASDAQ:APEN) Trading At A 20% Discount?

Today we will run through one way of estimating the intrinsic value of Apollo Endosurgery, Inc. ( NASDAQ:APEN ) by...
Seeking Alpha • Jun 28

Apollo Endosurgery: New Management Bounce Makes Weight Loss Specialist A Buy

Apollo Endosurgery is a medical device company developing innovative medical devices to advance gastrointestinal therapeutic endoscopy. The company's share price is +421% over the past 12 months and +130% since the arrival of a new CEO, Charles "Chas" McKhann in February. Although revenues fell ~18% between FY19 and FY20 owing to pandemic pressures, management is guiding for $55-57m of revenues in FY21. The company has 3 exciting growth opportunities - breakthrough device designation for its gastric balloon in NASH, a stand-alone weight loss indication for its OverStitch suturing device, and newly launched X-Tack. As such, shares still look cheap at ~$8.6, and a market cap of $233m undervalues the company and its opportunities, in my view.
분석 기사 • May 05

Is Apollo Endosurgery (NASDAQ:APEN) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Mar 24

A Look At The Intrinsic Value Of Apollo Endosurgery, Inc. (NASDAQ:APEN)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Apollo Endosurgery...
분석 기사 • Mar 03

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

Every investor in Apollo Endosurgery, Inc. ( NASDAQ:APEN ) should be aware of the most powerful shareholder groups...
분석 기사 • Feb 10

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

Potential Apollo Endosurgery, Inc. ( NASDAQ:APEN ) shareholders may wish to note that insider Neil Gagnon recently...
분석 기사 • Jan 31

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
분석 기사 • Dec 27

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

It is doubtless a positive to see that the Apollo Endosurgery, Inc. ( NASDAQ:APEN ) share price has gained some 155% in...
분석 기사 • Dec 01

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

Apollo Endosurgery, Inc. (NASDAQ:APEN), is not the largest company out there, but it led the NASDAQGM gainers with a...

주주 수익률

APENUS Medical EquipmentUS 시장
7D0.8%-0.5%0.9%
1Y67.8%-20.1%24.5%

수익률 대 산업: APEN은 지난 1년 동안 -20.1%의 수익을 기록한 US Medical Equipment 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: APEN은 지난 1년 동안 24.5%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is APEN's price volatile compared to industry and market?
APEN volatility
APEN Average Weekly Movement0.5%
Medical Equipment Industry Average Movement8.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

안정적인 주가: APEN는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.

시간에 따른 변동성: APEN의 주간 변동성은 지난 1년간 12%에서 1%로 감소했습니다.

회사 소개

설립직원 수CEO웹사이트
2005202Chas McKhannwww.apolloendo.com

Apollo Endosurgery, Inc. 기초 지표 요약

Apollo Endosurgery의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
APEN 기초 통계
시가총액US$579.72m
순이익 (TTM)-US$39.84m
매출 (TTM)US$76.86m
7.5x
주가매출비율(P/S)
-14.6x
주가수익비율(P/E)

APEN는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
APEN 손익계산서 (TTM)
매출US$76.86m
매출원가US$34.43m
총이익US$42.43m
기타 비용US$82.27m
순이익-US$39.84m

최근 보고된 실적

Dec 31, 2022

다음 실적 발표일

해당 없음

주당순이익(EPS)-0.69
총이익률55.20%
순이익률-51.84%
부채/자본 비율164.7%

APEN의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2023/04/06 15:40
종가2023/04/03 00:00
수익2022/12/31
연간 수익2022/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Apollo Endosurgery, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Matthew HewittCraig-Hallum Capital Group LLC
Frank TakkinenLake Street Capital Markets, LLC
Suraj KaliaNorthland Capital Markets